Effect of target-controlled infusion of remazolam on postoperative quality of patients with gynecologic malignant tumor after laparoscopic surgery

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300068713

Enrollment

Unknown

Registered

2023-02-28

Start date

2023-02-28

Completion date

Unknown

Last updated

2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gynecologic malignant tumor

Interventions

Group P:Propofol

Group R:Remazolam

Eligibility

Sex/Gender

Female

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: ?Age 18-65 years ?the American Society of Anesthesiologists (ASA) grade I-II Grade ? was able to conduct the Recovery Quality Rating Questionnaire

Exclusion criteria

Exclusion criteria: ?Allergic to drugs used in the study?severe heart and lung disease? psychiatric and neurological disorder?uncontrolled stable hypertension, diabetes ? women who underwent laparoscopy conversion to laparotomy ?severe organ dysfunction? women who were pregnant and lactating? alcoholics ? myasthenia gravis ? patients with severe depression ? schizophrenics

Design outcomes

Primary

Measure	Time frame
Qor-15 score;	—

Secondary

Measure	Time frame
Intraoperative vital signs;Partial pressure of end-respiratory carbon dioxide;Frequency of use of vasoactive drugs;Incidence of adverse events in the anesthesia recovery room;The dwell time of the PACU;Recovery time;Extubation time;Length of hospital stay;	—

Countries

China

Contacts

Public ContactJunling Li

Foshan Maternity & Child Healthcare Hospital

1694675001@qq.com18038863905

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026